Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 16/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28512196 | 0.84 | MAP3K5 (0.52) | MAP3K5 | |
| SCHEMBL30686028 | 0.84 | MAP3K5 (0.52) | MAP3K5 | |
| SCHEMBL23011962 | 0.81 | MAP3K5 (0.47) | MAP3K5ALDH1A1HPGDKDM4E | |
| SCHEMBL9910778 | 0.80 | L3MBTL1 (0.53) | MAP3K5ALDH1A1RETCDK2ITK | |
| SCHEMBL857728 | 0.79 | ALDH1A1 (0.43) | ALDH1A1HPGDHSD17B10KDM4EMAP4K4 | |
| SCHEMBL29217682 | 0.77 | CBLB (0.43) | MAP3K5KDM4E | |
| SCHEMBL28365584 | 0.74 | MAP3K5 (0.43) | MAP3K5RETCDK2ITKMERTK | |
| SCHEMBL15147819 | 0.73 | MAP3K5 (0.60) | MAP3K5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL13226000 | 0.72 | CYP1A2 (0.54) | MAP3K5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL29506348 | 0.72 | MAP3K5 (0.56) | MAP3K5RETCDK2ITKMERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569701-A | Preparation and application of compound with 1H-benzimidazole structure | 江西中医药大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118324752-A | Five-membered heterocyclic compound with phenyl substitution, and preparation and application thereof | 江西中医药大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-117756785-A | Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound | 江西中医药大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-110294746-B | Novel ASK1 inhibitor and application thereof | 山东轩竹医药科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220135527-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | MAP3K5 10/4885ALDH1A1 3134/4885HPGD 3579/4885 |
| US-20220135527-A1 | PROCESSES FOR PREPARING ASK1 INHIBITORS | MAP3K1, MAP3K6, MAP3K7 | MAP3K5 6/4885ALDH1A1 2697/4885HPGD 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.